CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort [Yahoo! Finance]
CERo Therapeutics Holdings, Inc. (CERO)
Company Research
Source: Yahoo! Finance
evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, today announced that it has dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid leukemia (AML). Per protocol, three patients are planned at this lowest dose level, and enrollment of the third subject may complete the initial cohort pending the outcome of protocol-defined safety assessments, including the dose-limiting toxicity (DLT) evaluation period. Stephen Strickland, Jr., M.D., MSCI, Director of Leukemia Research at Sarah Cannon Research Institute (SCRI) and lead investigator at the site where the third patient was dosed, commented, “Advancing to the third and final planned patient at the starting dose level represents an impor
Show less
Read more
Impact Snapshot
Event Time:
CERO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERO alerts
High impacting CERo Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERO
News
- CERo Therapeutics Announces Trading on OTCQB MarketGlobeNewswire
- Aggressive cancer warning signs revealed after JFK's granddaughter's diagnosis [FOX News]FOX News
- CERo Therapeutics (NASDAQ:CERO) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.MarketBeat
- CERo Therapeutics (NASDAQ:CERO) had its "hold" rating reaffirmed by analysts at D. Boral Capital.MarketBeat
- CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in DosingGlobeNewswire
CERO
Sec Filings
- 12/5/25 - Form S-1
- 12/2/25 - Form 424B3
- 12/2/25 - Form 424B3
- CERO's page on the SEC website